Comparison of the investigated ALL-BFM 2000 subcohort and the remaining (not analyzed) ALL-BFM 2000 patients
| . | ALL-BFM 2000 study participants with SR and IR risk disease not analyzed . | ALL-BFM 2000 subcohortanalyzed . | P . |
|---|---|---|---|
| Sex, N (%) | |||
| Male | 753 (53.3) | 295 (59.1) | |
| Female | 659 (46.7) | 204 (40.9) | .025* |
| Age N (%) | |||
| <10 y | 1097 (77.7) | 395 (79.2) | |
| ≥10 y | 315 (22.3) | 104 (20.8) | .496* |
| WBC, N (%) | |||
| <10 000 | 800 (56.7) | 214 (42.9) | |
| 10 000≤50 000 | 432 (30.6) | 180 (36.1) | |
| 50 000≤100 000 | 101 (7.2) | 61 (12.2) | |
| ≥100 000 | 79 (5.6) | 44 (8.8) | <.001* |
| Immunophenotype, N (%) | |||
| Precursor B-ALL | 1230 (87.1) | 433 (86.8) | |
| T-ALL | 121 (8.6) | 59 (11.8) | |
| Other | 6 (0.4) | 1 (0.2) | |
| Unknown | 55 (3.9) | 6 (1.2) | .115* |
| DNA index, N (%) | |||
| <1.16 | 702 (49.7) | 305 (61.1) | |
| ≥1.16 | 211 (14.9) | 82 (16.4) | |
| Unknown | 499 (35.3) | 112 (22.4) | .448* |
| TEL/AML1, N (%) | |||
| Positive | 332 (23.5) | 128 (25.7) | |
| Negative | 908 (64.3) | 347 (69.5) | |
| Unknown | 172 (12.2) | 24 (4.8) | .942* |
| Treatment protocol, N (%) | |||
| SR | 532 (37.7) | 212 (42.5) | |
| intermediate risk | 880 (62.3) | 287 (57.5) | .058* |
| MRD class | |||
| MRD-SR | 533 (48.6) | 212 (50.4) | |
| MRD-MR | 504 (45.9) | 195 (46.3) | |
| MRD-SER | 60 (5.5) | 14 (3.3) | .215* |
| 5-year survival rate | |||
| % (95% CI) | 95.7% (94.6–96.8) | 96.9% (95.4–98.5) | .087† |
| EFS (5 y), % (95% CI) | 88.1% (86.4–86.8) | 90.8 (88.2–93.4) | .182† |
| . | ALL-BFM 2000 study participants with SR and IR risk disease not analyzed . | ALL-BFM 2000 subcohortanalyzed . | P . |
|---|---|---|---|
| Sex, N (%) | |||
| Male | 753 (53.3) | 295 (59.1) | |
| Female | 659 (46.7) | 204 (40.9) | .025* |
| Age N (%) | |||
| <10 y | 1097 (77.7) | 395 (79.2) | |
| ≥10 y | 315 (22.3) | 104 (20.8) | .496* |
| WBC, N (%) | |||
| <10 000 | 800 (56.7) | 214 (42.9) | |
| 10 000≤50 000 | 432 (30.6) | 180 (36.1) | |
| 50 000≤100 000 | 101 (7.2) | 61 (12.2) | |
| ≥100 000 | 79 (5.6) | 44 (8.8) | <.001* |
| Immunophenotype, N (%) | |||
| Precursor B-ALL | 1230 (87.1) | 433 (86.8) | |
| T-ALL | 121 (8.6) | 59 (11.8) | |
| Other | 6 (0.4) | 1 (0.2) | |
| Unknown | 55 (3.9) | 6 (1.2) | .115* |
| DNA index, N (%) | |||
| <1.16 | 702 (49.7) | 305 (61.1) | |
| ≥1.16 | 211 (14.9) | 82 (16.4) | |
| Unknown | 499 (35.3) | 112 (22.4) | .448* |
| TEL/AML1, N (%) | |||
| Positive | 332 (23.5) | 128 (25.7) | |
| Negative | 908 (64.3) | 347 (69.5) | |
| Unknown | 172 (12.2) | 24 (4.8) | .942* |
| Treatment protocol, N (%) | |||
| SR | 532 (37.7) | 212 (42.5) | |
| intermediate risk | 880 (62.3) | 287 (57.5) | .058* |
| MRD class | |||
| MRD-SR | 533 (48.6) | 212 (50.4) | |
| MRD-MR | 504 (45.9) | 195 (46.3) | |
| MRD-SER | 60 (5.5) | 14 (3.3) | .215* |
| 5-year survival rate | |||
| % (95% CI) | 95.7% (94.6–96.8) | 96.9% (95.4–98.5) | .087† |
| EFS (5 y), % (95% CI) | 88.1% (86.4–86.8) | 90.8 (88.2–93.4) | .182† |